Bicara Therapeutics (NASDAQ:BCAX) Price Target Cut to $30.00 by Analysts at Morgan Stanley

Key Points

• Morgan Stanley cut its Bicara Therapeutics price target to $30 from $41 but maintained an “overweight” rating; at the stock’s $10 closing price, the target implies about 200% upside.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $30.83, despite several recent target reductions.
• Bicara reported a quarterly loss of $1.04 per share, wider than the $0.82 expected. The company said its $442.3 million cash balance should fund operations into the first half of 2029, with interim results from its pivotal FORTIFI-HN01 trial expected in mid-2027.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) had its price objective dropped by analysts at Morgan Stanley from $41.00 to $30.00 in a report issued on Tuesday, Benzinga reports. The firm currently has an "overweight" rating on the stock. Morgan Stanley's price objective would indicate a potential upside of 199.91% from the stock's previous close.

A number of other equities analysts have also recently issued reports on BCAX. BTIG Research cut their price target on Bicara Therapeutics from $39.00 to $37.00 and set a "buy" rating on the stock in a report on Tuesday. Wells Fargo & Company boosted their target price on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 12th. Wall Street Zen lowered shares of Bicara Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, October 31st. Wedbush reduced their price target on shares of Bicara Therapeutics from $33.00 to $24.00 and set an "outperform" rating for the company in a report on Thursday, October 29th. Finally, Benchmark reaffirmed a "buy" rating on shares of Bicara Therapeutics in a research note on Thursday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $30.83.

Bicara Therapeutics Price Performance

Shares of NASDAQ BCAX traded up $0.02 during midday trading on Tuesday, hitting $10.00. The stock had a trading volume of 296,939 shares, compared to its average volume of 750,991. Bicara Therapeutics has a fifty-two week low of $7.87 and a fifty-two week high of $30.99. The company's 50-day simple moving average is $17.89 and its 200 day simple moving average is $20.91. The firm has a market cap of $661.90 million, a P/E ratio of -3.21 and a beta of -0.33.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.22). Equities analysts expect that Bicara Therapeutics will post -3.49 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Ryan Cohlhepp sold 17,500 shares of the firm's stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total transaction of $400,750.00. Following the completion of the sale, the chief executive officer owned 181,641 shares in the company, valued at approximately $4,159,578.90. This trade represents a 8.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.80% of the company's stock.

Institutional Investors Weigh In On Bicara Therapeutics

Several large investors have recently added to or reduced their stakes in BCAX. Sterling Capital Management LLC boosted its holdings in shares of Bicara Therapeutics by 457.0% during the third quarter. Sterling Capital Management LLC now owns 1,387 shares of the company's stock worth $26,000 after purchasing an additional 1,138 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in Bicara Therapeutics during the 3rd quarter valued at approximately $63,000. China Universal Asset Management Co. Ltd. grew its stake in Bicara Therapeutics by 15.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,074 shares of the company's stock worth $224,000 after purchasing an additional 1,617 shares during the period. Arizona State Retirement System purchased a new stake in shares of Bicara Therapeutics in the 2nd quarter worth about $241,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in Bicara Therapeutics during the second quarter worth about $272,000.

Key Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara said enrollment is substantial in its pivotal FORTIFI-HN01 trial, with interim-analysis results expected in mid-2027. It also reported $442.3 million in cash, which it expects to fund operations into the first half of 2029—supporting development plans while limiting near-term financing concerns. Bicara third-quarter results and business update
• Neutral Sentiment: Stifel Nicolaus cut its price target from $45 to $43 and BTIG Research lowered its target from $39 to $37. Both firms maintained “buy” ratings, leaving targets well above the current share price, though the reductions temper their outlooks. Stifel Nicolaus ratings BTIG Research ratings
• Negative Sentiment: BCAX reported a third-quarter loss of $1.04 per share, wider than the $0.82 loss analysts expected. The earnings miss may weigh on shares, particularly as the company remains clinical-stage and investors await trial results. Bicara third-quarter earnings report

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses.

The company's lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.